NGOs Urge EU Ministers To Resist 'Industry Pressure' and Reform RnD Model, Raise Regulatory Standards
This article was originally published in SRA
Executive Summary
A group of 25 civil society bodies and NGOs have called on EU member states to resist what they describe as 'pressure from the pharmaceutical industry to eliminate critical elements of proposed EU Council Conclusions' that are intended to improve the balance between intellectual property measures designed to encourage innovation and the need to ensure patients have access to affordable medicines1.
You may also be interested in...
MEPs Slate EU Industry Practices In Report On Barriers To Medicines Access
The European Parliament’s environment and public health committee has produced a set of recommendations for a new approach to tackling barriers to medicines in the EU. There’s a particular focus on pricing strategies, intellectual property, and delays to generic competition.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.